Valion Bio names Thomas Jensen Board Chair; touts $35.6M government funding for Entolimod ARS program

Valion Bio, Inc.

Thomas H. Jensen named Board Chair of Valion Bio; he is CEO and a director of Nasdaq-listed Allarity Therapeutics, which he has led since December 2023.
Entolimod is an investigational TLR5 agonist being developed as a potential medical countermeasure for acute radiation syndrome (ARS), holding FDA Fast Track and Orphan Drug designations for ARS.
Entolimod development has received approximately $35.6 million in non-dilutive funding from several U.S. government agencies.
Jensen said that to the company's knowledge there is no FDA-approved treatment for gastrointestinal ARS; longer term he sees potential in cancer supportive care.
Jensen is working with Interim CEO Dean Zikria and President/COO/CFO Lisa Wolf; drug supply is controlled through wholly owned U.S.-based CDMO Velocity Bioworks.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.